KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Diluted Average) (2016 - 2025)

Sarepta Therapeutics (SRPT) has 8 years of Shares Outstanding (Diluted Average) data on record, last reported at $106.6 million in Q2 2025.

  • For Q2 2025, Shares Outstanding (Diluted Average) rose 7.56% year-over-year to $106.6 million; the TTM value through Jun 2025 reached $106.6 million, up 7.56%, while the annual FY2011 figure was $129.6 million, N/A changed from the prior year.
  • Shares Outstanding (Diluted Average) reached $106.6 million in Q2 2025 per SRPT's latest filing, up from $100.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $106.6 million in Q2 2025 and bottomed at $88.7 million in Q2 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $96.8 million, with a median of $99.1 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 13.0% in 2024, then increased 7.56% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $88.9 million in 2023, then grew by 13.0% to $100.4 million in 2024, then grew by 6.15% to $106.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $106.6 million in Q2 2025, $100.4 million in Q3 2024, and $99.1 million in Q2 2024.